Entrada Therapeutics Management
Management criteria checks 3/4
Entrada Therapeutics' CEO is Dipal Doshi, appointed in Aug 2017, has a tenure of 6.67 years. total yearly compensation is $3.49M, comprised of 16.2% salary and 83.8% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $1.61M. The average tenure of the management team and the board of directors is 3.7 years and 3.1 years respectively.
Key information
Dipal Doshi
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 16.2% |
| CEO tenure | 6.7yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$3m | US$565k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$78m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$6m | US$425k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$41m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$906k | US$385k | -US$27m |
Compensation vs Market: Dipal's total compensation ($USD3.49M) is above average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Dipal's compensation has been consistent with company performance over the past year.
CEO
Dipal Doshi (47 yo)
6.7yrs
Tenure
US$3,491,063
Compensation
Mr. Dipal Doshi serves as Director of The Children's Health Fund. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics, Inc. since August 2017 and served as its President since A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.7yrs | US$3.49m | 0.38% $ 1.6m | |
| President & COO | 4.4yrs | US$1.54m | 0.42% $ 1.8m | |
| Chief Scientific Officer | 6.6yrs | US$1.62m | 0.40% $ 1.7m | |
| CFO & Treasurer | 3.4yrs | no data | 0.26% $ 1.1m | |
| General Counsel | 4yrs | no data | no data | |
| Senior Vice President of People | 2.7yrs | no data | no data | |
| Chief Corporate Affairs Officer | 1.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data |
3.7yrs
Average Tenure
49.5yo
Average Age
Experienced Management: TRDA's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.7yrs | US$3.49m | 0.38% $ 1.6m | |
| Director | 3.3yrs | US$81.94k | 0.19% $ 826.4k | |
| Industry Leader & Independent Director | 2.9yrs | US$96.94k | 0% $ 0 | |
| Independent Chairman of the Board | 7.5yrs | US$123.44k | 0% $ 0 | |
| Industry Leader & Independent Director | less than a year | no data | 0% $ 0 | |
| Director | less than a year | no data | no data |
3.1yrs
Average Tenure
56.5yo
Average Age
Experienced Board: TRDA's board of directors are considered experienced (3.1 years average tenure).